Nucleic acid mediated disruption of HIV fusogenic peptide interactions
OwnerDennis Macejak, Lawrence Blatt +1inventors
InventorsDennis Macejak, Lawrence Blatt, James McSwiggen
Life of this patent
Estimating the term…
Abstract
The present invention relates to nucleic acid aptamers that bind to HIV envelope glycoprotein, gp120 and/or gp41 and methods for their use alone or in combination with other therapies, such as HIV RT inhibitors and HIV protease inhibitors. Also disclosed are nucleic acids such as siRNA, antisense, and enzymatic nucleic acid molecules that can modulate the expression of HIV env genes and HIV viral replication. The compounds and methods of the invention are expected to inhibit HIV viral fusion, cell entry, gene expression, and replication.
Claims20
A short interfering RNA (siRNA) molecule that down-regulates expression of a HIV envelope glycoprotein (env) gene by RNA interference.
Dependencies are inferred from the claim text.